August 18, 2014 7:50 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
In a report published Monday, Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating on
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
(NASDAQ: BIIB), but removed the $395.00 price target.In the report, Morgan Stanley noted, “Friday's approval was in-line with expectations following a 3 month PDUFA date extension. The label appears consistent with Avonex. Both drugs demonstrated similar annualized relapse rates (ARR) vs placebo, ~30-34% for Avonex and 36% for Plegridy, but Plegridy is dosed every two weeks while Avonex is dosed weekly. The monthly dose of Plegridy achieved a lower ARR (~28%) and is not labeled, though it may be used off-label for certain patients.”Biogen Idec closed on Friday at $342.47.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.